Sign In
Buy 0HR2
Cme Group Earnings Calls
| Release date | Oct 22, 2025 |
| EPS estimate | $2.63 |
| EPS actual | $2.68 |
| EPS Surprise | 1.90% |
| Revenue estimate | 1.591B |
| Revenue actual | 1.538B |
| Revenue Surprise | -3.38% |
| Release date | Jul 23, 2025 |
| EPS estimate | $2.91 |
| EPS actual | $2.82 |
| EPS Surprise | -3.09% |
| Revenue estimate | 1.596B |
| Revenue actual | 1.692B |
| Revenue Surprise | 6.00% |
| Release date | Apr 23, 2025 |
| EPS estimate | $2.80 |
| EPS actual | $2.62 |
| EPS Surprise | -6.43% |
| Revenue estimate | 1.62B |
| Revenue actual | 1.642B |
| Revenue Surprise | 1.40% |
| Release date | Feb 12, 2025 |
| EPS estimate | $2.45 |
| EPS actual | $2.49 |
| EPS Surprise | 1.63% |
| Revenue estimate | 1.541B |
| Revenue actual | 1.525B |
| Revenue Surprise | -1.02% |
Last 4 Quarters for Cme Group
Below you can see how 0HR2.L performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 12, 2025 |
| Price on release | $249.48 |
| EPS estimate | $2.45 |
| EPS actual | $2.49 |
| EPS surprise | 1.63% |
| Date | Price |
|---|---|
| Feb 06, 2025 | $243.95 |
| Feb 07, 2025 | $245.34 |
| Feb 10, 2025 | $242.99 |
| Feb 11, 2025 | $241.87 |
| Feb 12, 2025 | $249.48 |
| Feb 13, 2025 | $249.30 |
| Feb 14, 2025 | $247.87 |
| Feb 17, 2025 | $246.85 |
| Feb 18, 2025 | $246.37 |
| 4 days before | 2.27% |
| 4 days after | -1.25% |
| On release day | -0.0722% |
| Change in period | 0.99% |
| Release date | Apr 23, 2025 |
| Price on release | $253.95 |
| EPS estimate | $2.80 |
| EPS actual | $2.62 |
| EPS surprise | -6.43% |
| Date | Price |
|---|---|
| Apr 15, 2025 | $264.65 |
| Apr 16, 2025 | $262.85 |
| Apr 17, 2025 | $265.12 |
| Apr 22, 2025 | $261.87 |
| Apr 23, 2025 | $253.95 |
| Apr 24, 2025 | $264.45 |
| Apr 25, 2025 | $265.93 |
| Apr 28, 2025 | $267.35 |
| Apr 29, 2025 | $269.41 |
| 4 days before | -4.04% |
| 4 days after | 6.09% |
| On release day | 4.14% |
| Change in period | 1.80% |
| Release date | Jul 23, 2025 |
| Price on release | $277.21 |
| EPS estimate | $2.91 |
| EPS actual | $2.82 |
| EPS surprise | -3.09% |
| Date | Price |
|---|---|
| Jul 17, 2025 | $277.43 |
| Jul 18, 2025 | $275.60 |
| Jul 21, 2025 | $276.17 |
| Jul 22, 2025 | $275.14 |
| Jul 23, 2025 | $277.21 |
| Jul 24, 2025 | $273.42 |
| Jul 25, 2025 | $280.27 |
| Jul 28, 2025 | $275.52 |
| Jul 29, 2025 | $277.94 |
| 4 days before | -0.0802% |
| 4 days after | 0.264% |
| On release day | -1.37% |
| Change in period | 0.184% |
| Release date | Oct 22, 2025 |
| Price on release | $269.80 |
| EPS estimate | $2.63 |
| EPS actual | $2.68 |
| EPS surprise | 1.90% |
| Date | Price |
|---|---|
| Oct 16, 2025 | $264.55 |
| Oct 17, 2025 | $263.88 |
| Oct 20, 2025 | $267.05 |
| Oct 21, 2025 | $268.21 |
| Oct 22, 2025 | $269.80 |
| Oct 23, 2025 | $270.44 |
| Oct 24, 2025 | $269.94 |
| Oct 27, 2025 | $271.51 |
| Oct 28, 2025 | $269.28 |
| 4 days before | 1.98% |
| 4 days after | -0.193% |
| On release day | 0.237% |
| Change in period | 1.79% |
Cme Group Earnings Call Transcript Summary of Q3 2025
CME Group reported solid Q3 2025 results with average daily volume of 25.3 million contracts (the second-highest Q3 ever) and record open interest (126 million contracts at quarter-end). Revenue was $1.5 billion (down 3% year-over-year from a very strong prior-year quarter); adjusted net income was $978 million and adjusted EPS was $2.68 (both slightly above last year and among the highest quarters in company history). Market data was a standout, a record $203 million (up 14%). Adjusted expenses remained well-controlled (adjusted operating margin 68.4%). Management reiterated innovation-led growth priorities: successful product launches (Solana and XRP futures, credit futures, 1-oz gold futures, agricultural weekly options), FX Spot+ adoption, and the new BrokerTec Chicago cash venue. Key strategic items: extension of FTSE Russell license through 2037, expanded DTCC cross-margining, plan to offer 24/7 crypto futures & options beginning early 2026, and a partnership with FanDuel to distribute event-based contracts. Proceeds from the OSTTRA sale were about $1.5 billion; management will present capital deployment recommendations to the Board (options include buybacks/dividends). Google partnership progress and tokenized cash work support 24/7 trading plans and operational modernization; Google-related spend for 2025 is embedded in guidance (~$100M expected total). Guidance: 2025 adjusted operating expenses (ex-license fees) now expected at ~$1.625 billion (about $10M below prior guidance). Risks cited include regulatory outcomes for event/sports contracts, evolving customer demand for 24/7 in non-crypto asset classes, and forward-looking uncertainties.
